Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation
Targeting a specific cancer protein with newer drugs shows promise in certain leukemia patients, with tests helping predict who will benefit most.
This comprehensive review maps XPO1's leukemogenic role in AML and synthesizes preclinical and clinical evidence for selinexor and eltanexor, including response biomarkers and resistance mechanisms. It argues for molecularly selected populations and biomarker-guided dosing as the path forward for SINE inhibitors in AML.
What the study was
- Study design
- Systematic review of preclinical and clinical literature
- Population
- AML patients across clinical trials and preclinical models
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical and Translational Medicine
Why it surfaced
High-quality AML-focused review of XPO1 inhibitors with clinical trial synthesis and biomarker framework; useful for AML precision therapy decision support. Review design caps score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.